XBP1 and graft versus host disease: In contrast, a study performed in human graft vs. host disease (GVHD), has shown that DCs-specific sXBP1 deletion strongly suppress alloreactive CD4 T cells, and pharmacological block of spliced XBP1 protects against rejection.